Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The prognosis for colorectal cancer (CRC) patients with liver metastasis remains poor, and the molecular mechanisms driving CRC liver metastasis are not fully understood. Tumor-derived hypoxia-induced extracellular vesicles have emerged as key players in inducing angiogenesis by transferring noncoding RNAs. However, the specific role of CRC-derived hypoxic extracellular vesicles (H-EVs) in regulating premetastatic microenvironment (PMN) formation by inducing angiogenesis remains unclear. Our study demonstrates that H-EVs induce angiogenesis and liver metastasis. Through microRNA microarray analysis, we identified a reduction in miR-6084 levels within H-EVs. We found that miR-6084 inhibited angiogenesis by being transferred to endothelial cells via EVs. In endothelial cells, miR-6084 directly targeted angiopoietin like 4 (ANGPTL4) mRNA, thereby suppressing angiogenesis through the ANGPTL4-mediated JAK2/STAT3 pathway. Furthermore, we uncovered that specificity protein 1 (SP1) acted as a transcription factor regulating miR-6084 transcription, while hypoxia-inducible factor 1A (HIF1A) decreased miR-6084 expression by promoting SP1 protein dephosphorylation and facilitating ubiquitin-proteasome degradation in SW620 cells. In clinical samples, we observed low expression of miR-6084 in plasma-derived EVs from CRC patients with liver metastasis. In summary, our findings suggest that CRC-derived H-EVs promote angiogenesis and liver metastasis through the HIF1A/SP1/miR-6084/ANGPTL4 axis. Additionally, miR-6084 holds promise as a diagnostic and prognostic biomarker for CRC liver metastasis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288965 | PMC |
| http://dx.doi.org/10.1172/jci.insight.189503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset.
Clin Exp Metastasis
September 2025
Medical Oncology Unit, Macerata Hospital, Macerata, Italy.
Recent years have seen the development and advent of novel combinatorial strategies based on immunotherapy, and immune checkpoint inhibitor (ICI) - based treatment has established itself as a mainstay in the treatment of metastatic urothelial carcinoma (UC). Herein, we aimed to validate the prognostic value of a previously developed score, the Prognostic Immunotherapy Score (PIS), including female sex, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) and liver metastases, in patients treated with pembrolizumab for advanced UC from the ARON-2 dataset. We retrospectively analyzed clinical data from Metastatic UC patients diagnosed at age ≥ 18 years.
View Article and Find Full Text PDFPrognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Colorectal Cancer Survival: A Multicenter Retrospective Cohort Study.
J Gastrointest Cancer
September 2025
Firoozabadi Clinical Research Development Unit (F A CRD U), Iran , University of Medical Sciences (IUMS), Tehran, Iran.
Background: Colorectal cancer (CRC) has become one of the major health burdens in the world with high mortality rates, especially at the advanced stages. The C-reactive protein (CRP)-albumin-lymphocyte (CALLY) index is a novel multidimensional biomarker combining systemic inflammation, nutritional status, and immune function. This study evaluated the association between the CALLY index and overall survival (OS) as well as recurrence-free survival (RFS) in colorectal cancer (CRC) patients.
View Article and Find Full Text PDFRisk Factors in Predicting Radiologically Occult Metastatic Disease from Pancreatic Ductal Adenocarcinoma: A Single-Institution Experience with Routine Preoperative Magnetic Resonance Imaging.
J Gastrointest Surg
September 2025
Department of Surgery, Mayo Clinic, Jacksonville, Florida. Electronic address:
Background: Limited data exists regarding the incidence of aborted pancreatic surgery due to radiologically occult metastatic disease (ROMD). This study presents a single-institution experience aimed at identifying potential risk factors associated with ROMD of patients undergoing routine preoperative magnetic resonance imaging with pancreatic ductal adenocarcinoma (PDAC) METHODS: Patients with PDAC taken for curative intent pancreatic surgery between January 2012 and December 2022 following preoperative imaging MRI protocol were retrospectively reviewed, and those who had aborted surgery due to ROMD were identified. Binary logistic regression analysis was performed to identify potential predictors of ROMD.
View Article and Find Full Text PDF27-hydroxycholesterol roles in respiratory disease pathogenesis.
Int Immunopharmacol
September 2025
Department of Immunology, School of Laboratory Medicine, Bengbu Medical University, Anhui 233030, China; Anhui Province Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical University, Anhui 233030, China. Electronic address:
27-Hydroxycholesterol (27-HC) is an oxidative metabolite of cholesterol, enzymatically produced by the mitochondrial cytochrome P450 enzyme, sterol 27-hydroxylase (CYP27A1). Endogenous 27-HC maintains cholesterol homeostasis primarily via the selective inhibition of sterol regulatory element-binding protein 2 (SREBP-2). By binding to liver X receptors (LXR) and estrogen receptors (ER), 27-HC exerts diverse biological effects.
View Article and Find Full Text PDFPredictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab.
Int J Clin Oncol
September 2025
Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-Shimbashi, Minato-Ku, Tokyo, 105-8471, Japan.
Background: Despite durable benefits of ipilimumab and nivolumab in metastatic renal cell carcinoma (mRCC), early progressive disease (PD), defined as disease progression within 3 months, occurs, and its predictors remain unclear. We aimed to investigate the clinical factors associated with early PD in patients with mRCC treated with this regimen.
Methods: A retrospective analysis of a multi-institutional database identified 193 patients with mRCC treated with ipilimumab plus nivolumab.